DJIA 17,776.12 -200.19 -1.11%
NASDAQ 4,900.89 -46.56 -0.94%
S&P 500 2,067.89 -18.35 -0.88%
market minute promo

MannKind Corp (NASDAQ: MNKD)



company name or ticker

MannKind Reports Narrower Y/Y Loss in Q4, Afrezza in Focus - Analyst Blog

JPM Securities Picks Through Biotech News For Winners

MannKind Corporation in Transition

A drug on the market for two weeks makes for a boring earnings call.

MannKind Is Tripling Production To Meet Future Demand

MannKind's Accounting Is 'Murky,' MLV Analyst Says

MannKind's (MNKD) CEO Hakan Edstrom on Q4 2014 Results - Earnings Call Transcript

MannKind Corporation Posts In-Line Q4; Expense Falls 35%

MannKind (MNKD) Q4 2014 Results - Earnings Call Webcast

Meet MannKind Corporation's New Boss (No, the Other One)

Sanofi's new CEO Olivier Brandicourt will have an impact on the success of MannKind's Afrezza.

3 Critical Questions MannKind Shareholders Need to Contemplate in 2015

With potentially game-changing diabetes therapy Afrezza now launched, shareholders can turn their attention to these three important questions.
See More Articles...